News | Latest Breaking News Stories & Headlines

Novo Nordisk cut its full-year sales and operating profit forecasts for the second time this year earlier this month

Novo Nordisk woes prompt Denmark to cut growth forecast

Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and tariffs on Danish goods exported to the US, the country's economy ministry said today.

Business • 29 Aug

Novo Nordisk became Europe's most valuable listed company following the launch of Wegovy in 2021

Novo Nordisk freezes hiring for non-critical jobs

Wegovy-maker NovoNordisk has implemented a global hiring freeze covering job roles that are not critical for its business, the company said today.

Business • 20 Aug

At its peak in June 2024, Novo was worth as much as $615 billion

Novo Nordisk picks Doustdar as new CEO, shares plunge

Novo Nordisk named Maziar Mike Doustdar as its new chief executive today, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug Wegovy is falling behind in a race it started.

Business • 29 Jul

Novo Nordisk regains crown as Europe's most valuable firm

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP today.

Business • 13 Jun

Lars Fruergaard Jorgensen, the outging CEO of Novo Nordisk

Novo Nordisk's CEO to step down amid market struggle

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Business • 16 May

Novo Nordisk said its first quarter earnings rose by 22% on the same time last year

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the US to start to recover once a ban on compound copycats is enforced this month, its CEO said today after the company cut its 2025 forecasts.

Business • 07 May

Novo Holdings is the controlling shareholder of obesity drugmaker Novo Nordisk

Novo Holdings doubles income and returns in 2024

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record €8 billion in 2024, it said today.

Business • 02 Apr

SAP shares have clocked a total return of 160% since the end of 2022

SAP unseats Novo Nordisk as Europe's largest company

German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market capitalisation today.

Business • 24 Mar

During the fourth quarter, sales of Wegovy more than doubled to 19.9 billion crowns from 9.6 billion a year ago

Novo Nordisk sees slower sales growth in 2025

Wegovy maker Novo Nordisk has today forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.

Business • 05 Feb

Sales of Novo Nordisk's Wegovy totalled $2.49 billion in the third quarter

Novo Nordisk narrows 2024 guidance range

Novo Nordisk has today reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.

Business • 06 Nov 24

Eli Lilly's weight-loss drug Zepbound has crossed $1 billion in sales for the first time in a quarter

Eli Lilly raises annual profit forecast on Zepbound sales

Eli Lilly has today raised its annual profit forecast and boosted its revenue expectations by $3 billion, as it benefited from ramped up manufacturing capacity for its highly popular weight-loss and diabetes drugs.

Business • 08 Aug 24

Novo Nordisk has today raised its 2024 sales forecast but cut its profit outlook

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Novo Nordisk has today trimmed its full-year profit outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, stirring worries among investors about stiffening competition from Eli Lilly.

Business • 07 Aug 24

Novo Nordisk has quadrupled its US supply of starter doses Wegovy since Decembr

Novo Nordisk ups outlook fuelled by obesity drug demand

Novo Nordisk has today raised its 2024 outlook and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.

Business • 02 May 24

Novo Nordisk has risen in the global rankings to the 12th most valuable company from 14 previously

Novo valuation surpasses Tesla on experimental drug data

Novo Nordisk has surpassed Tesla in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.

Business • 08 Mar 24

In December, the Irish arm of Novo Nordisk lodged plans with South Dublin County Council for a new filling and packaging facility at Grange Castle Business Park West

Council seeks new plans from Novo Nordisk on Dublin plant

The maker of 'blockbuster' weight loss and diabetes drug, Ozempic, Novo Nordisk has been requested to lodge revised plans for its large scale Dublin plant arising from local residents' concerns.

Business • 26 Feb 24

Novo Nordisk's parent to buy Catalent for $16.5 billion

Novo Nordisk has notched a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for $16.5 billion.

Business • 06 Feb 24

Novo Nordisk said it expects sales growth this year between 16% and 25%

Novo Nordisk sees double-digit full year growth

Novo Nordisk has today forecast another year of double-digit record sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy.

Business • 31 Jan 24

Nestle chief executive Mark Schneider sees opportunities ahead for the company

Weight-loss drugs no threat to coffee business - Nestle

Nestle sees no threat to its huge coffee business from the rising popularity of weight-loss drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, its chief executive Mark Schneider said this week.

Business • 21 Dec 23

Novo Nordisk is to invest more than $6 billion as it seeks to meet booming demand for its Wegovy weight-loss treatment and other drugs

Novo Nordisk to invest $6 billion in expanding plant

Obesity drug maker Novo Nordisk said it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.

Business • 10 Nov 23

Novo stops Ozempic kidney trial after signs of success

Novo Nordisk has said it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.

Business • 11 Oct 23

Surging demand for Wegovy and Novo's diabetes drug Ozempic, have sent the company's shares and earnings to record highs

Novo Nordisk launches weight-loss drug Wegovy in UK

Novo Nordisk has today launched its weight-loss injection Wegovy in Britain, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.

Business • 04 Sep 23

Novo Nordisk is riding a wave of demand for its highly effective diabetes and weight-loss drugs Ozempic and Wegovy

Novo Nordisk briefly overtakes LVMH in European ranking

Danish drugmaker Novo Nordisk briefly unseated LVMH as Europe's most valuable listed company in intraday trading today, ending the French luxury group's two and a half year-long reign at the top.

Business • 01 Sep 23

Novo Nordisk